Drugs / C2403
Trials 0
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT06643130 Comparator | Dec 2024 → Apr 2026 overdue | hyperlipidemia, hypertensive disorder | JW Pharmaceutical | Recruiting | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | C2403 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06643130 ↗ |
| Route | Oral | “For 8 weeks(PO, QD)” NCT06643130 ↗ |